Apixaban is a generic oral tablet that’s prescribed for certain types of blood clots. It’s available as the brand-name drug Eliquis. The cost of apixaban, with and without insurance, can depend on ...
Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot ...
Pharmacists predict the medication shortages will get worse before they get better Some people living with heart conditions, stroke risks, eye infections and bipolar disorder are among those unable to ...
In older patients with atrial fibrillation (AF), apixaban seems to improve outcomes relative to warfarin regardless of frailty status, whereas other direct oral anticoagulants (DOACs) appear ...
When older adults with atrial fibrillation (AF) are starting on a direct oral anticoagulant (DOAC) for stroke prevention, they may be better off with apixaban than rivaroxaban. In a study of claims ...
But do these drugs really herald the end of warfarin, and how do doctors decide which of the three new agents to use? Two experts have quite different views of the situation. Dr Alexander Turpie ...
A large, population-based study of patients with atrial fibrillation (AF) and valvular heart disease (VHD) found that use of apixaban was associated with a lower rate of ischemic stroke or systemic ...
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...
Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, ...
Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action. It has a ...
The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of apixaban, having considered evidence on the nature of venous thromboembolism and the value placed on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results